Keynote: COVID-19 and the Future of Gene Editing to Treat Blood Cancers

Jennifer Hancock, PsyD

John F. DiPersio, MD, PhD

Virginia E. and Sam J. Golman Professor in Medicine
Chief, Division of Oncology
Director, Center for Gene and Cellular Immunotherapy
Deputy Director, Alvin J. Siteman Cancer Center
Professor of Medicine, Pathology & Immunology

Dr. DiPersio’s research focuses on fundamental and translational aspects of leukemia and stem cell biology. These studies include identification of genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking, and clinical and translational programs in both leukemia/myelodysplastic syndrome and transplantation immunology.

Among his many accomplishments, Dr. DiPersio was instrumental in developing a drug called plerixafor and ruxolitnib in 2019 that were approved by the U.S. Food and Drug Administration in 2008 and 2019 respectively for the treatment of multiple myeloma, non-Hodgkin’s lymphoma and graft versus host disease.

For a complete bio, click here.